Women's Health Policy

ABORTION IN THE U.S.

KFF infographic explaining who regulates mifepristone, showing four entities and their roles: the U.S. Food and Drug Administration approves and regulates medications for safety and effectiveness; state legislatures pass laws that can restrict or protect access; courts rule on legal cases affecting regulation; and Congress can pass federal legislation influencing regulation.

Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

Louisiana sued the FDA in October 2025, claiming the FDA’s 2023 regulatory change eliminating the requirement that mifepristone be dispensed in-person—allowing it to be mailed or dispensed at retail pharmacies—harm the state's ability to enforce its abortion ban. This brief reviews the Louisiana v. FDA case now before the Supreme Court, and provides an overview of the other pending litigation involving mifepristone, as well as the mounting tension between states seeking to protect abortion and those banning the provision of abortion.

CONTRACEPTIve care IN THE U.S.

New and noteworthy

Over-the-Counter Oral Contraceptive Pills

In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

featured

A promotional image for the the KFF Health Policy 101 Issues in Women’s Health chapter

Health Policy Issues in Women’s Health

Examine the core health coverage and access issues —shaped by federal and state policies—that affect women’s health today, including health coverage and costs, reproductive health services, maternal health, mental health, and intimate partner violence.

State Profiles for Women’s Health

Explore the latest national and state-specific data and policies on women’s health. Topics include health status, insurance and Medicaid coverage, use of preventive services, sexual health, maternal and infant health, and abortion policies. Many indicators provide state-level information for women of different racial and ethnic groups.

The essentials
  • Women’s Health Insurance Coverage

    This factsheet reviews major sources of coverage for women residing in the U.S., discusses the ACA's impact on coverage, and the coverage challenges that many women continue to face.
  • Medicaid Coverage for Women

    This data note presents key data points describing the current state of the Medicaid program as it affects women, including eligibility, reproductive health, chronic conditions, and more.
  • Dobbs: What are the Implications for Racial Disparities?

    This analysis examines the implications of the Dobbs decision and state restrictions on abortion coverage for racial disparities in access to care and health outcomes.
  • State Health Facts: Women's Health Indicators

    Information on women’s health status, utilization of services, health insurance coverage, family planning and childbirth, and abortion statistics and policies.
  • Key Facts on Abortion in the United States

    This report answers some key questions about abortion in the United States and presents data collected before the overturn of Roe v. Wade.

Subscribe to KFF Emails

Choose which emails are best for you.
Sign up here

Filter

821 - 830 of 870 Results

  • KFF News Release

    The Title X Network Has Largely Returned Under the Biden Administration 

    News Release

    A new KFF brief examines the return of grantees and clinic sites to the Title X network under the Biden Administration, which reversed Trump Administration regulations that prohibited Title X sites from providing abortion referrals and having co-located abortion services. For more than 50 years, the federal Title X program has provided family planning services to nearly four million people a year through a network of clinics. The program is part of the U.S. public…

  • A National Survey of OBGYNs’ Experiences After Dobbs

    Report

    This report, based on a nationally representative survey of office-based OBGYNs practicing in the United States, examines the provision of sexual and reproductive health care provided by OBGYNs before and after the Dobbs decision, comparing the experiences of OBGYNs practicing in states where abortion is fully banned, states with gestational restrictions, and states where abortion remains available under most circumstances.

  • What the Data Show: Abortions Later in Pregnancy 

    News Release

    Following recent news about former President Trump’s potential support for a national 16-week abortion ban, KFF examines the data about how often abortions later in pregnancy occur, exploring the potential reasons why, and detailing the various laws that regulate access to abortions later in pregnancy. The updated analysis considers 2021 CDC data, before the Dobbs decision, in a post-Dobbs policy landscape. The analysis shows that abortions at or after 21 weeks are uncommon and represent…

  • Since Dobbs, Few Large Firms Have Changed Their Plan’s Abortion Coverage Policy

    News Release

    According to an analysis of responses to KFF’s Employer Health Benefits Survey in 2023, relatively few (8%) large firms (with 200 or more workers) offering health benefits report reducing or expanding coverage for abortion since the U.S. Supreme Court overturned Roe v. Wade with the Dobbs v. Jackson ruling. Since Dobbs, 3% of these large firms reduced or eliminated coverage for abortion where it is legal. Meanwhile, 12% of large firms whose largest plan covers…

  • 3 Charts: The Cost and Coverage of Opill—the First FDA-approved Over-the-Counter Daily Oral Contraceptive Pill in the United States 

    News Release

    The first FDA-approved over-the-counter daily oral contraceptive pill in the United States— Perrigo’s Opill— is now available for pre-order at major online retailers and will soon be available in stores. Although the new over-the-counter pill could broaden access to contraceptive options in the United States, KFF research suggests consumers are likely to face some hurdles if they seek to have their plan cover the costs. For example, while federal policy requires most private health insurance…

  • 1 in 8 Voters Say Abortion Is Most Important to Their Vote: They Lean Democratic, Support Biden, and Want Abortion to Be Legal

    News Release

    About 1 in 8 voters (12%) now say that abortion is the most important issue for their vote in the 2024 elections, highlighting how the issue could motivate groups of voters who largely say abortion should be legal in all or most cases, a new KFF Health Tracking Poll finds. The issue resonates with certain key groups of women voters. More than 1 in 4 Black women voters (28%), and about a fifth of Democratic…

  • The Supreme Court, Medication Abortion, and the FDA: What’s at Stake?

    News Release

    In advance of oral arguments about access to medication abortion before the Supreme Court on March 26, KFF examines how a Court ruling for the plaintiffs would limit access to mifepristone blocking its use in telehealth and distribution through pharmacies, including in states where abortion is legal and protected. In addition, it could potentially weaken the role of the Food and Drug Administration (FDA) in drug reviews—something the Court has never done before. As part…